CAR-engineered NK cells for the treatment of glioblastoma: turning innate effectors into precision tools for cancer immunotherapy
Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and
currently incurable. Despite multimodal treatment regimens, median survival in unselected …
currently incurable. Despite multimodal treatment regimens, median survival in unselected …
Preclinical and clinical studies of CAR-NK-cell therapies for malignancies
H Li, W Song, Z Li, M Zhang - Frontiers in Immunology, 2022 - frontiersin.org
The development of chimeric antigen receptor T (CAR-T) cell therapy, a specific type of
immunotherapy, in recent decades was a fantastic breakthrough for the treatment of …
immunotherapy, in recent decades was a fantastic breakthrough for the treatment of …
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
Recurrent glioblastoma (rGBM) remains a major unmet medical need, with a median overall
survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase …
survival of less than 1 year. Here we report the first six patients with rGBM treated in a phase …
ERK is a pivotal player of chemo-immune-resistance in cancer
IC Salaroglio, E Mungo, E Gazzano, J Kopecka… - International journal of …, 2019 - mdpi.com
The extracellular signal-related kinases (ERKs) act as pleiotropic molecules in tumors,
where they activate pro-survival pathways leading to cell proliferation and migration, as well …
where they activate pro-survival pathways leading to cell proliferation and migration, as well …
Interleukin 13 promotes long-term recovery after ischemic stroke by inhibiting the activation of STAT3
D Chen, J Li, Y Huang, P Wei, W Miao, Y Yang… - Journal of …, 2022 - Springer
Background Microglia/macrophages are activated after cerebral ischemic stroke and can
contribute to either brain injury or recovery by polarizing microglia/macrophage into …
contribute to either brain injury or recovery by polarizing microglia/macrophage into …
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
K Mortezaee, J Majidpoor - Cellular Oncology, 2022 - Springer
Macrophages are the most abundant and one of the most critical cells of tumor immunity.
They provide a bridge between innate and adaptive immunity through releasing cytokines …
They provide a bridge between innate and adaptive immunity through releasing cytokines …
[HTML][HTML] Interleukin 13 receptor alpha 2 (IL13Rα2): expression, signaling pathways and therapeutic applications in cancer
Abstract Interleukin 13 receptor alpha 2 (IL13Rα2) is increasingly recognized as a relevant
player in cancer invasion and metastasis. Despite being initially considered a decoy …
player in cancer invasion and metastasis. Despite being initially considered a decoy …
Transferrin receptor-targeted nanocarriers: overcoming barriers to treat glioblastoma
Glioblastoma multiforme (GBM) is the most common and lethal type of brain tumor, and the
clinically available approaches for its treatment are not curative. Despite the intensive …
clinically available approaches for its treatment are not curative. Despite the intensive …
EGFRvIII: An Oncogene with Ambiguous Role
A Rutkowska, E Stoczyńska-Fidelus, K Janik… - Journal of …, 2019 - Wiley Online Library
Epidermal growth factor receptor variant III (EGFRvIII) seems to constitute the perfect
therapeutic target for glioblastoma (GB), as it is specifically present on up to 28–30% of GB …
therapeutic target for glioblastoma (GB), as it is specifically present on up to 28–30% of GB …
The glioma immune landscape: A double-edged sword for treatment regimens
S Mahajan, MHH Schmidt, U Schumann - Cancers, 2023 - mdpi.com
Simple Summary Glioblastoma (GBM) is the most severe and aggressive form of primary
brain tumor with a poor prognosis. Currently, the treatment for GBM treatment involves …
brain tumor with a poor prognosis. Currently, the treatment for GBM treatment involves …